Kesios Therapeutics Limited is a UK-based biotechnology company developing novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company is focused on the discovery and development of novel drug candidates for the treatment of multiple myeloma and other malignancies which target aberrant NF-κB signaling, via a novel drug target (the GADD45β/MKK7 complex). The NF-κB signaling pathway is involved in driving normal cell death but when aberrantly activated allows cancer cells to survive. The company has established a pipeline of programmes targeting this pathway, with KES-0001, the company's lead drug candidate, about to enter clinical studies as a potential treatment for multiple myeloma. Additional pre-clinical research programmes will explore KES-0001 in haematological malignancies, colon cancer and other solid tumors.Kesios is led by an experienced management team and is supported by a syndicate of leading international investors. The company operates from offices and laboratories based at the Imperial College Incubator, London, UK.